Dr. Reddy's Laboratories - ADR Financials
$11.85
As on 09-Sep-2026 13:39EDT
Market cap
$10,021 Mln
Revenue (TTM)
$332,834 Mln
P/E Ratio
29.3
P/B Ratio
2.5
Div. Yield
0.7 %
Income Statement (₹ Mln) |
TTM | Mar-26 | Mar-25 | Mar-24 | Mar-23 | Mar-22 | Mar-21 | Mar-20 | Mar-19 | Mar-18 | Mar-17 |
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Operating Revenue
|
332,834.17
|
353,471.64
|
325,535.00
|
279,164.00
|
245,879.00
|
214,391.00
|
|||||
|
Cost of Revenue
|
165,910.29
|
166,952.91
|
135,107.00
|
115,557.00
|
106,536.00
|
100,551.00
|
|||||
|
Gross Profit
|
166,923.88
|
186,518.73
|
190,428.00
|
163,607.00
|
139,343.00
|
113,840.00
|
|||||
|
Operating Expenses
|
131,728.10
|
137,651.00
|
118,585.00
|
95,878.00
|
82,199.00
|
84,364.00
|
|||||
|
Operating Profit (EBIT)
|
35,195.77
|
48,867.73
|
71,843.00
|
67,729.00
|
57,144.00
|
29,476.00
|
|||||
|
Other Income
|
--
|
--
|
--
|
--
|
--
|
--
|
|||||
|
Profit before Tax
|
41,359.76
|
57,678.93
|
76,784.00
|
71,870.00
|
60,367.00
|
32,298.00
|
|||||
|
Provision for Tax
|
8,582.66
|
12,995.83
|
19,539.00
|
16,186.00
|
15,300.00
|
8,730.00
|
|||||
|
Profit after Tax (Net Income)
|
33,166.55
|
45,087.15
|
56,544.00
|
55,684.00
|
45,067.00
|
23,568.00
|
|||||
|
Minority Interest
|
389.00
|
384.00
|
-701.00
|
--
|
--
|
--
|
|||||
|
Consolidated Profit
|
25,570.00
|
--
|
56,551.00
|
55,779.00
|
45,073.00
|
23,568.00
|
Liabilities (₹ Mln) |
TTM | Mar-26 | Mar-25 | Mar-24 | Mar-23 | Mar-22 | Mar-21 | Mar-20 | Mar-19 | Mar-18 | Mar-17 |
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Shareholder's Funds
|
383,428.00
|
369,598.17
|
333,388.00
|
280,550.00
|
230,991.00
|
190,527.00
|
|||||
|
Minority Interest
|
389.00
|
--
|
--
|
--
|
--
|
--
|
|||||
|
Non-Current Liabilities
|
31,229.00
|
30,702.89
|
25,431.00
|
10,929.00
|
5,018.00
|
8,285.00
|
|||||
|
Current Liabilities
|
157,341.00
|
164,248.64
|
130,392.00
|
96,039.00
|
85,845.00
|
94,015.00
|
|||||
|
Total Liabilities
|
732,646.00
|
567,876.51
|
492,989.00
|
387,518.00
|
321,854.00
|
292,827.00
|
Assets (₹ Mln) |
TTM | Mar-26 | Mar-25 | Mar-24 | Mar-23 | Mar-22 | Mar-21 | Mar-20 | Mar-19 | Mar-18 | Mar-17 |
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Non-Current Assets
|
275,974.00
|
271,879.80
|
242,877.00
|
139,469.00
|
117,601.00
|
110,971.00
|
|||||
|
Current Assets
|
299,331.00
|
295,996.71
|
250,112.00
|
248,049.00
|
204,253.00
|
181,856.00
|
|||||
|
Total Assets
|
732,646.00
|
567,876.51
|
492,989.00
|
387,518.00
|
321,854.00
|
292,827.00
|
|||||
|
Total Debt*
|
71,952.00
|
75,809.86
|
46,766.00
|
20,020.00
|
13,472.00
|
33,845.00
|
|||||
|
Net Current Assets
|
141,990.00
|
134,409.00
|
119,720.00
|
152,010.00
|
118,534.00
|
83,264.00
|
Cashflow (₹ Mln) |
TTM | Mar-26 | Mar-25 | Mar-24 | Mar-23 | Mar-22 | Mar-21 | Mar-20 | Mar-19 | Mar-18 | Mar-17 |
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Cash From Operating Activities
|
--
|
56,645.66
|
46,428.00
|
45,433.00
|
58,873.00
|
28,108.00
|
|||||
|
Cash Flow from Investing Activities
|
--
|
-70,533.76
|
-58,077.00
|
-40,283.00
|
-41,373.00
|
-26,387.00
|
|||||
|
Cash from Financing Activities
|
--
|
13,395.67
|
18,911.00
|
-3,763.00
|
-26,861.00
|
-2,422.00
|
|||||
|
Net Cash Inflow / Outflow
|
--
|
--
|
--
|
--
|
--
|
--
|
Financials Ratios |
TTM | Mar-26 | Mar-25 | Mar-24 | Mar-23 | Mar-22 | Mar-21 | Mar-20 | Mar-19 | Mar-18 | Mar-17 |
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Adjusted EPS (₹)
|
39.81
|
54.01
|
67.77
|
66.77
|
54.13
|
28.34
|
|||||
|
Cash EPS (₹)
|
--
|
78.67
|
88.22
|
84.57
|
69.14
|
42.55
|
|||||
|
Adjusted Book Value (₹)
|
--
|
442.74
|
399.60
|
336.41
|
277.42
|
229.07
|
|||||
|
Dividend per Share (₹)
|
--
|
--
|
--
|
--
|
--
|
--
|
|||||
|
Cash Flow per Share (₹)
|
--
|
67.85
|
55.65
|
54.48
|
70.71
|
33.79
|
|||||
|
Free Cash Flow per Share (₹)
|
--
|
38.45
|
14.42
|
21.58
|
48.05
|
10.89
|
Profitability Ratios |
TTM | Mar-26 | Mar-25 | Mar-24 | Mar-23 | Mar-22 | Mar-21 | Mar-20 | Mar-19 | Mar-18 | Mar-17 |
|---|---|---|---|---|---|---|---|---|---|---|---|
|
ROCE (%)
|
--
|
10.92
|
16.61
|
20.43
|
19.23
|
20.75
|
|||||
|
ROE (%)
|
8.88
|
12.83
|
18.42
|
21.77
|
21.38
|
24.44
|
|||||
|
ROA (%)
|
4.76
|
8.50
|
12.84
|
15.70
|
14.66
|
15.90
|
|||||
|
EBIT Margin (%)
|
11.08
|
17.43
|
24.46
|
26.36
|
25.13
|
15.51
|
|||||
|
Net Margin (%)
|
9.96
|
12.76
|
17.37
|
19.95
|
18.33
|
10.99
|
|||||
|
Cash Profit Margin (%)
|
--
|
--
|
--
|
--
|
--
|
--
|
Growth Ratios |
TTM | Mar-26 | Mar-25 | Mar-24 | Mar-23 | Mar-22 | Mar-21 | Mar-20 | Mar-19 | Mar-18 | Mar-17 |
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Revenue Growth (%)
|
-0.43
|
0.09
|
0.17
|
0.14
|
0.15
|
82.89
|
|||||
|
EBIT Growth (%)
|
-53.96
|
-22.61
|
8.20
|
19.07
|
85.82
|
9,076.52
|
|||||
|
Net Profit Growth (%)
|
-40.27
|
-20.26
|
1.54
|
23.56
|
91.22
|
10,049.50
|
|||||
|
EPS Growth (%)
|
-41.56
|
-0.20
|
0.02
|
0.23
|
0.91
|
100.44
|
|||||
|
Book Value Growth (%)
|
9.58
|
--
|
--
|
--
|
--
|
--
|
Solvency Ratios |
TTM | Mar-26 | Mar-25 | Mar-24 | Mar-23 | Mar-22 | Mar-21 | Mar-20 | Mar-19 | Mar-18 | Mar-17 |
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Debt to Equity
|
--
|
0.21
|
0.14
|
0.07
|
0.06
|
0.18
|
|||||
|
Short term debt to equity ratio
|
0.16
|
0.17
|
0.12
|
0.05
|
0.05
|
0.15
|
|||||
|
Current Ratio
|
1.90
|
1.80
|
1.92
|
2.58
|
2.38
|
1.93
|
|||||
|
Quick Ratio
|
1.39
|
1.35
|
1.37
|
1.92
|
1.81
|
1.39
|
|||||
|
Interest Coverage
|
10.86
|
15.66
|
28.14
|
43.00
|
43.27
|
34.71
|
Operating Efficiency Ratios |
TTM | Mar-26 | Mar-25 | Mar-24 | Mar-23 | Mar-22 | Mar-21 | Mar-20 | Mar-19 | Mar-18 | Mar-17 |
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Debtors to sales (%)
|
37.38
|
28.07
|
33.73
|
34.15
|
33.84
|
37.44
|
|||||
|
Asset Turnover
|
0.48
|
0.67
|
0.74
|
0.79
|
0.80
|
1.45
|
|||||
|
Receivable days
|
--
|
107.99
|
115.08
|
116.80
|
121.42
|
69.10
|
|||||
|
Inventory Days
|
--
|
159.82
|
181.99
|
177.35
|
170.66
|
93.55
|
|||||
|
Payable days
|
--
|
57.76
|
56.23
|
62.27
|
57.99
|
29.32
|
|||||
|
Cash Conversion Cycle
|
--
|
210.04
|
240.84
|
231.88
|
234.09
|
133.32
|